Research team finds GLP-1 obesity drugs cause metabolic instability
Updated
Updated · 매일경제 · Apr 29
Research team finds GLP-1 obesity drugs cause metabolic instability
10 articles · Updated · 매일경제 · Apr 29
Seoul National University Hospital said the study by Professor Baek Sun-ha, Professor Noh Jong-ryul and researcher Lee Jae-wang reviewed more than 120 recent clinical observations and biological datasets.
The researchers said prolonged treatment creates a redox metabolism bottleneck, with rising oxidative stress and weakening antioxidant defences contributing to muscle loss, micronutrient depletion and poor absorption of essential nutrients.
Published in Energy Metabolism Flow, the paper urges obesity care to move beyond weight alone and include routine monitoring of muscle mass, nutrition and metabolic indicators during GLP-1 treatment.
As millions use GLP-1s, what monitoring is essential to prevent permanent muscle and bone damage?
GLP-1 drugs promise metabolic health, but can long-term use secretly trigger a systemic collapse?
The Double-Edged Sword of GLP-1RAs: Cardiovascular Benefits and the Emerging Challenge of Lean Mass Loss
Overview
GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized metabolic treatment by causing substantial weight loss and reducing major cardiovascular events in patients. However, prolonged use leads to chronic energy flux constriction from sustained caloric restriction, which causes oxidative stress and depletion of vital cellular components like NAD⁺. This depletion results in significant loss of lean body mass, worsening insulin resistance and reducing physical strength and organ health. Additionally, these drugs cause gastrointestinal side effects that can worsen nutritional deficits. Addressing these challenges is essential to maximize benefits while preserving muscle and metabolic health during therapy.